| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H29N5O3 |
| Molecular Weight | 471.5509 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)C1=C2NCC[C@@H](C3CCN(CC3)C(=O)C=C)N2N=C1C4=CC=C(OC5=CC=CC=C5)C=C4
InChI
InChIKey=RNOAOAWBMHREKO-QFIPXVFZSA-N
InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1
| Molecular Formula | C27H29N5O3 |
| Molecular Weight | 471.5509 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Zanubrutinib (formerly known as BGB-3111) was developed by BeiGene as a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). The drug forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK activity. BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion, thus Zanubrutinib inhibits malignant B-cell proliferation and reduces tumor growth. Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with mantle cell lymphoma (MCL). On August 31, 2021, the Food and Drug Administration approved zanubrutinib for adult patients with Waldenström’s macroglobulinemia (WM).
CNS Activity
Originator
Approval Year
Sample Use Guides
160 mg orally twice daily or 320 mg orally once daily; swallow whole with water and with or without food
Route of Administration:
Oral
The in vitro cell-based activity of zanubrutinib on BTK was evaluated in mantle cell lymphoma (MCL) cell lines and showed that BTK was inhibited with an IC50 of 1.8 nM. In vitro activity was evaluated on a panel of 23 hematologic cancer cell lines. Zanubrutinib demonstrated the most prominent growth inhibitory activity on 3 MCL cell lines and a diffuse large B-cell lymphoma (DLBCL) cell line.
Showing 1 to 5 of 10 entries
![Structure of 4,5,6,7-Tetrahydro-2-(4-phenoxyphenyl)-7-(4-piperidinyl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile](/img/42412b6f-ee41-4134-ba3d-b7f6bf3aa543.svg "Structure of 4,5,6,7-Tetrahydro-2-(4-phenoxyphenyl)-7-(4-piperidinyl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile")
![Structure of tert-Butyl 4-[3-carbamoyl-2-(4-phenoxyphenyl)-4H,5H,6H,7H-pyrazolo[1,5-a]pyrimidin-7-yl]piperidine-1-carboxylate](/img/a9ef7490-f289-40fe-84bc-9ce690a04cb9.svg "Structure of tert-Butyl 4-[3-carbamoyl-2-(4-phenoxyphenyl)-4H,5H,6H,7H-pyrazolo[1,5-a]pyrimidin-7-yl]piperidine-1-carboxylate")
![Structure of tert-Butyl 2-[(2E)-3-(dimethylamino)prop-2-enoyl]piperidine-1-carboxylate](/img/9586dd68-ef41-49f3-bd56-f4ebfa67f8aa.svg "Structure of tert-Butyl 2-[(2E)-3-(dimethylamino)prop-2-enoyl]piperidine-1-carboxylate")
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| blood-to-plasma ratio | PHARMACOKINETIC |
[0.7 to 0.8] (average) |
|
|||
| Biological Half-life | PHARMACOKINETIC |
[2 to 4] hours (average) |
|
|||
| Tmax | PHARMACOKINETIC |
2 hours (average) |
ORAL ADMINISTRATION |
|
||
| Volume of Distribution | PHARMACOKINETIC |
881 LITERS (average) |
|
|||